Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

Pradhan, Rajesh; Dey, Anuradha; Taliyan, Rajeev; Puri, Anu; Kharavtekar, Sanskruti Santosh; Dubey, Sunil Kumar

doi:10.3390/pharmaceutics15010246

Cited by 16 publications

(9 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The core of the NPs was made up of siRNA–protamine complex, and the shell contained an aptamer ligand for targeting CD44 expressed on TNBC cells. The outcome of the study indicated that the formulation targeting TNBC cells demonstrated enhanced anticancer effects [ 168 , 169 ].…”

Section: Potential Applications Of Precision-medicine Therapy For Tnbcmentioning

confidence: 99%

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Subhan

Parveen

Shah

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.

show abstract

Section: Potential Applications Of Precision-medicine Therapy For Tnbcmentioning

confidence: 99%

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Subhan

Parveen

Shah

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…TNBC is a prominent cause of cancer deaths in women due to its aggressive nature and a lack of effective therapy methods (Berger et al 2021;Akter et al 2023). Studies have shown that TNBC formation and occurrence involved abnormally active mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK), which may provide TNBC the capacity to multiply and withstand apoptosis (Kim et al 2016;Ryu and Sohn 2021;Pradhan et al 2023;Yang et al 2023a, b).…”

Section: Introductionmentioning

confidence: 99%

Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies

Abdulmalek,

Saleh,

Shahin

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Oncogenic microRNA (miRNA), especially miRNA-21 upregulation in triple-negative breast cancer (TNBC), suggests a new class of therapeutic targets. In this study, we aimed to create GE11 peptide-conjugated small interfering RNA-loaded chitosan nanoparticles (GE11-siRNA-CSNPs) for the targeting of EGFR overexpressed TNBC and selectively inhibit miRNA-21 expression. A variety of in-silico and in vitro cellular and molecular studies were conducted to investigate the binding affinities of specific targets used as well as the anticancer efficacies and mechanisms of GE11-siRNA-CSNPs in TNBC cells. An in-silico assessment reveals a distinct binding affinity of miRNA-21 with siRNA as well as between the extracellular domain of EGFR and synthesized peptides. Notably, the in vitro results showed that GE11-siRNA-CSNPs were revealed to have better cytotoxicity against TNBC cells. It significantly inhibits miRNA-21 expression, cell migration, and colony formation. The results also indicated that GE11-siRNA-CSNPs impeded cell cycle progression. It induces cell death by reducing the expression of the antiapoptotic gene Bcl-2 and increasing the expression of the proapoptotic genes Bax, Caspase 3, and Caspase 9. Additionally, the docking analysis and immunoblot investigations verified that GE1-siRNA-CSNPs, which specifically target TNBC cells and suppress miRNA-21, can prevent the effects of miRNA-21 on the proliferation of TNBC cells via controlling EGFR and subsequently inhibiting the PI3K/AKT and ERK1/2 signaling axis. The GE11-siRNA-CSNPs design, which specifically targets TNBC cells, offers a novel approach for the treatment of breast cancer with improved effectiveness. This study suggests that GE11-siRNA-CSNPs could be a promising candidate for further assessment as an additional strategy in the treatment of TNBC. Graphical Abstract

show abstract

“…The siRNA drug was formulated with cationic lipid-assisted PEG-PLA NPs to target cyclin-dependent kinase 1 for TNBC therapy. The NPs inhibited c-myc overexpressing TNBC cells by reducing CDK-1 expression [ 64 , 65 ]. Further, aptamer-guided siRNA NPs targeting CD44 expression in TNBC were prepared [ 65 ].…”

Section: Introductionmentioning

confidence: 99%

“…The NPs inhibited c-myc overexpressing TNBC cells by reducing CDK-1 expression [ 64 , 65 ]. Further, aptamer-guided siRNA NPs targeting CD44 expression in TNBC were prepared [ 65 ]. The results of the study demonstrated that the drug exhibited improved anticancer effects against TNBC [ 65 , 66 ].…”

Section: Introductionmentioning

confidence: 99%

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

2023

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed cancer among women. Breast cancer is also the key reason for worldwide cancer-related deaths among women. The application of small interfering RNA (siRNA)-based drugs to combat breast cancer requires effective gene silencing in tumor cells. To overcome the challenges of drug delivery to tumors, various nanosystems for siRNA delivery, including lipid-based nanoparticles that protect siRNA from degradation for delivery to cancer cells have been developed. These nanosystems have shown great potential for efficient and targeted siRNA delivery to breast cancer cells. Lipid-based nanosystems remain promising as siRNA drug delivery carriers for effective and safe cancer therapy including breast cancer. Lipid nanoparticles (LNPs) encapsulating siRNA enable efficient and specific silencing of oncogenes in breast tumors. This review discusses a variety of lipid-based nanosystems including cationic lipids, sterols, phospholipids, PEG-lipid conjugates, ionizable liposomes, exosomes for effective siRNA drug delivery to breast tumors, and the clinical translation of lipid-based siRNA nanosystems for solid tumors.

show abstract

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

Cited by 16 publications

References 243 publications

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

Contact Info

Product

Resources

About